ArticleBMC gastroenterology2025
The value of systemic inflammatory response index in evaluating the prognosis of postoperative patients with stage II colon cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExploring the prognostic value of systemic inflammatory response index (SIRI) for 3-year disease-free survival (DFS) in stage II colon cancer patients after radical surgery.
methodsA retrospective analysis was conducted on 87 patients with stage II colon cancer. Patients were divided by 3-year DFS status: poor prognosis group (DFS event; n = 28) vs. good prognosis group (event-free; n = 59). Univariate analysis and multivariate Cox regression analysis were performed to identify the influencing factors on postoperative prognosis of stage II colon cancer patients. Receiver operating characteristic (ROC) curve was used to evaluate the predictive value of various influencing factors on postoperative prognosis of stage II colon cancer patients. Kaplan-Meier method and Log-rank test were used to compare survival differences among patients with different SIRI levels.
resultsOne week before surgery, the neutrophil to lymphocyte ratio (NLR) level in the poor prognosis group was significantly lower (P < 0.05). The levels of SIRI, carcinoembryonic antigen (CEA), carbohydrate antigen 19 − 9 (CA19-9), carbohydrate antigen 125 (CA125), and carbohydrate antigen 72 − 4 (CA72-4) in the poor prognosis group were significantly higher (P < 0.05). NLR, SIRI, CEA, CA19-9, CA125, and CA72-4 were all independent risk factors for the prognosis of postoperative patients with stage II colon cancer. The area under the curve (AUC) for predicting patient prognosis using NLR, SIRI, CEA, CA19-9, CA125, and CA72-4 were 0.726, 0.828, 0.693, 0.741, 0.706, and 0.605, respectively. The optimal cutoff value for SIRI was 1.41, with a sensitivity of 0.67 and a specificity of 0.93. There was a significant difference in the 3-year disease-free survival rate between stage II colon cancer patients with SIRI ≥ 1.41 and SIRI < 1.41 after surgery (P < 0.05).
conclusionPreoperative SIRI predicts early recurrence risk (3-year DFS) more effectively than traditional biomarkers. DFS was significantly higher in patients with SIRI < 1.41.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.